Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection In Second-Line Advanced Prostate Cancer …

Published October 3, 2010

Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection In Second-Line Advanced Prostate Cancer …
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate …
Read more on Medical News Today

‘Legal weed,’ K2 incense, readily available in Central Florida
Authorities, drug experts worry the new generation weed products could be dangerous Incense and herbal smoking blends that mimic the high of marijuana are popping up in mom-and-pop convenience stores throughout Central Florida.
Read more on Orlando Sentinel

Sanofi Lixisenatide Diabetes Treatment Had Significant Phase Three Results
Sanofi-Aventis SA said the experimental diabetes drug lixisenatide combined with its best- seller Lantus helped patients better control the level of sugar in their blood.
Read more on Bloomberg